PBPK Re­sour­ces

PK-SIM® andMOBI® for PBPK and QUANTITATIVE SYSTEMS PHARMACOLOGY

Getting started with PK-Sim

• Physiologically based pharmacokinetic models for prediction of complex CYP2C8 and OATP1B1 (SLCO1B1) drug-drug-gene interactions: a modeling network of gemfibrozil, repaglinide, pioglitazone, rifampicin, clarithromycin and itraconazole. 
  https://doi.org/10.1007/s40262-019-00777-x

• A comprehensive whole-body physiologically based pharmacokinetic model of dabigatran etexilate, dabigatran and dabigatran glucuronide in healthy adults and renally impaired patients.
  https://doi.org/10.1007/s40262-019-00776-y

• Translational PBPK modeling of the protein therapeutic and CD95L inhibitor asunercept to develop dose recommendations for its first use in pediatric glioblastoma patients.
  https://doi.org/10.3390/pharmaceutics11040152 

• Physiologically-based pharmacokinetic models for CYP1A2 drug-drug interaction prediction: a modeling network of fluvoxamine, theophylline, caffeine, rifampicin, and midazolam.
  https://doi.org/10.1002/psp4.12397 

• A quantitative systems pharmacology kidney model of diabetes associated renal hyperfiltration and the effects of SGLT inhibitors. 
  https://doi.org/10.1002/psp4.12359 

• PBPK models for CYP3A4 and P‐gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin. 
  https://doi.org/10.1002/psp4.12343 

• The feasibility of physiologically based pharmacokinetic modeling in forensic medicine illustrated by the example of morphine. 
  https://doi.org/10.1007/s00414-017-1754-8 

• A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification. 
  https://doi.org/10.1007/s00280-017-3447-x